Marketing Mix Analysis of Salarius Pharmaceuticals, Inc. (SLRX)
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Salarius Pharmaceuticals, Inc. (SLRX) Bundle
In the ever-evolving realm of pharmaceuticals, Salarius Pharmaceuticals, Inc. (SLRX) stands at the forefront of innovation, specifically in the fight against cancer. By focusing on epigenetic enzyme inhibitors and their primary drug candidate, Seclidemstat, they aim to revolutionize treatments for hard-to-treat cancers. But what lies beneath this mission? Explore the intricacies of their marketing mix encompassing Product, Place, Promotion, and Price, and discover how Salarius is positioning itself in a competitive landscape.
Salarius Pharmaceuticals, Inc. (SLRX) - Marketing Mix: Product
Specializes in cancer therapeutics.
Salarius Pharmaceuticals is dedicated to developing innovative therapies specifically designed for cancer treatment. The company is engaged in research and development focused on providing targeted treatments for various forms of cancer.
Focus on epigenetic enzyme inhibitors.
The company emphasizes its expertise in epigenetic enzyme inhibitors, aiming to leverage this technology to offer unique therapeutic options that modify gene expression associated with cancer progression.
Primary drug candidate: Seclidemstat.
Salarius's lead product candidate is Seclidemstat (also known as SP-2577), which is currently undergoing clinical trials. Seclidemstat targets a wide range of cancers by inhibiting the enzyme lysine-specific demethylase 1 (LSD1).
Targets advanced cancers and solid tumors.
Seclidemstat is designed to treat advanced cancers and solid tumors, which often have limited treatment options. The focus includes:
- Soft tissue sarcoma
- Acute myeloid leukemia (AML)
- Additional solid tumor types
Develops treatments for hard-to-treat cancers.
Salarius Pharmaceuticals is committed to addressing unmet medical needs in the oncology space by developing therapies for cancers that are typically hard to treat. The company is particularly focused on:
- *Combination therapies* that enhance the efficacy of existing treatments
- *Personalized medicine* approaches to cater treatment plans to individual patients
| Key Product Features | Details |
|---|---|
| Product Name | Seclidemstat (SP-2577) |
| Target Enzyme | LYS1 (Lysine-specific demethylase 1) |
| Indications | Soft tissue sarcoma, AML, solid tumors |
| Clinical Trial Phases | Phase 1/2 |
| Estimated Market Size (2025) | $55 billion (global oncology market) |
| Funding (as of 2023) | $34 million raised in Series A financing |
Salarius continues to explore partnerships and collaborations to expedite the development of Seclidemstat and enhance its positioning in the competitive oncology market.
Salarius Pharmaceuticals, Inc. (SLRX) - Marketing Mix: Place
Headquarters in Houston, Texas
Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas. The company operates in a location with a strong biotech presence, benefiting from the local ecosystem of research and development.
Operates Primarily Within the United States
The company primarily focuses on the U.S. market for its product distribution. As of the last financial report, around 85% of its operations occur within the United States.
Collaborates with Global Research Institutions
Salarius collaborates with prominent global research institutions. In 2022, they partnered with over 10 major research centers, enhancing their clinical trial capabilities and broadening their market reach.
Clinical Trials Conducted in Various Locations
Salarius has conducted clinical trials across various locations in the United States, including:
| Clinical Trial Site | City | State | Trial Phase |
|---|---|---|---|
| Texas Children's Hospital | Houston | Texas | Phase 1 |
| Johns Hopkins Hospital | Baltimore | Maryland | Phase 2 |
| UCLA Medical Center | Los Angeles | California | Phase 1/2 |
| Cleveland Clinic | Cleveland | Ohio | Phase 2 |
Accessible Through Various Healthcare Providers
Products from Salarius Pharmaceuticals are accessible through a network of various healthcare providers. The distribution strategy includes:
- Hospital Pharmacies: Engaging with over 500 hospital pharmacies nationwide.
- Oncology Clinics: Partnerships with approximately 300 oncology clinics to distribute cancer treatment products.
- Specialty Pharmacies: Collaborations with around 200 specialty pharmacies that focus on high-cost and complex medications.
Salarius Pharmaceuticals, Inc. (SLRX) - Marketing Mix: Promotion
Engages in Scientific Conferences
Salarius Pharmaceuticals participates in numerous scientific conferences annually, facilitating connections with healthcare professionals and researchers. In 2022, Salarius presented at over 10 major conferences, including the American Society of Clinical Oncology (ASCO) annual meeting and the Society of Surgical Oncology (SSO) conference.
Published Research in Medical Journals
Salarius has emphasized the importance of publishing research findings in reputable medical journals. In 2023, the company had 4 significant publications in peer-reviewed journals, highlighting the efficacy of its lead product, Seclidemstat, in treating various cancers. These publications reached over 1,200 citations collectively, illustrating the impact of its research.
Collaborates with Key Opinion Leaders
The company actively collaborates with key opinion leaders (KOLs) within the oncology field. In 2023, Salarius focused on engaging with over 15 prominent KOLs to enhance the credibility and visibility of its products. These collaborations have led to the endorsement of Salarius’ therapies in various clinical settings.
Uses Digital Marketing and Social Media
Salarius Pharmaceuticals leverages digital marketing strategies effectively. In 2022, the company's website attracted over 100,000 unique visitors. In addition, the firm boasts a social media following of more than 20,000 across platforms like Twitter, LinkedIn, and Facebook, driving awareness and engagement.
Educational Webinars and Seminars
Salarius conducts educational webinars and seminars to disseminate knowledge about its products and the latest research findings. In 2023, Salarius hosted 5 major webinars, with an average attendance of 300 participants per session, providing insights into innovative treatment strategies and opportunities for Q&A with specialists.
| Year | Conferences Participated | Published Research Papers | Key Opinion Leaders Engaged | Unique Website Visitors | Social Media Followers | Webinars Held |
|---|---|---|---|---|---|---|
| 2022 | 10 | 3 | 10 | 100,000 | 15,000 | 3 |
| 2023 | 10 | 4 | 15 | 100,000 | 20,000 | 5 |
Salarius Pharmaceuticals, Inc. (SLRX) - Marketing Mix: Price
Clinical drugs under trial phase
Salarius Pharmaceuticals is focused on developing novel cancer therapeutics. As of Q3 2023, the company has its lead drug candidate, Seclidemstat, under clinical trials for various indications, including synovial sarcoma and other solid tumors. The pricing details for these treatments remain unavailable until post-commercialization.
Pricing details to follow post-commercialization
The pricing strategy for Salarius' drugs will be influenced by several factors, including regulatory approvals, market demand, and comparative clinical efficacy. For instance, the company's potential commercial drugs could be priced in line with similar oncology treatments, which typically range between $10,000 to $150,000 annually, depending on the indication and treatment regimen.
Strategies to make treatments cost-effective
In alignment with affordability for patients, Salarius Pharmaceuticals aims to implement various strategies that enhance the cost-effectiveness of their treatments:
- Utilizing bio-similar treatment methodologies to lower production costs.
- Engaging in value-based pricing models to reflect treatment outcomes.
- Implementing patient assistance programs to provide financial support.
Partnering for funding and grants
Salarius Pharmaceuticals actively seeks partnerships for funding and grants to support their research and commercialization efforts. For example, in 2021, the company secured approximately $5 million in funding from the National Institutes of Health (NIH) to assist in the development of Seclidemstat. These partnerships aim to reduce the financial burden of bringing drugs to market and ultimately affect pricing strategies.
Focus on affordable patient access
Salarius is committed to ensuring affordable access for patients requiring their therapies. This includes:
- Establishing tiered pricing strategies based on the economic status of different patient populations.
- Participating in co-pay assistance programs to minimize out-of-pocket costs.
- Collaborating with insurers to promote coverage policies that support patient access to necessary treatments.
| Funding Source | Amount Secured | Year |
|---|---|---|
| National Institutes of Health (NIH) | $5 million | 2021 |
| Private Investments | $10 million | 2023 |
In conclusion, Salarius Pharmaceuticals, Inc. (SLRX) exemplifies a dynamic approach within the biotechnology sector through its well-defined marketing mix. With a focus on innovative cancer therapeutics and epigenetic enzyme inhibitors, their product strategy is driven by the promising drug candidate, Seclidemstat, targeting tough-to-treat solid tumors. Strategically situated in Houston, Texas, the company not only operates across the United States but also engages in collaborations with prestigious global research institutions, ensuring access to clinical trials. Their promotional tactics, ranging from scientific conferences to digital marketing, enhance visibility and education within the healthcare community, while their pricing strategy aims at maintaining affordable patient access. Overall, Salarius continues to position itself as a pioneering force in transforming cancer care.